Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Classificação em ações #13828
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Preço da ação
$4.36
Valor de mercado
$457.32M
Variação (1 dia)
0.69%
Variação (1 ano)
289.29%
País
US
Negociar Relmada Therapeutics, Inc. (RLMD)

Categoria

Histórico de preços das ações de Relmada Therapeutics, Inc. (RLMD)
Preço de fecho mais alto: $4.68 em 2026-08-01

Preço de fecho mais baixo: $11.43 em 2014-06-01
Histórico de preços das ações da Relmada Therapeutics, Inc. de 2014 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 10.22%
2025 860.47%
2024 -36.35%
2023 -17.50%
2022 -78.37%
2021 -41.31%
2020 -14.84%
2019 756.21%
2018 52.34%
2017 -6.63%
2016 -71.17%
2015 -80.90%
2014 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.01 -13.08%
AU
$138.80 476.17%
US
$749.90 5.87%
CH